Aphios

Enhanced therapeutics for cancers and side-effects, infectious diseases, CNS disorders, health maintenance, APIs and equipment

Aphios has developed super critical fluids technologies and equipment for drug discovery and manufacturing of natural pharmaceuticals.

The company isolates research chemicals and APIs from plants and marine organisms using SuperFluids extraction, from microgram to kilogram scale.

The page states that breast cancer will affect 1 of every 8 women in the United States, with around 230,000 new cases and 40,000 deaths each year, and that prostate cancer will affect 1 of every 6 men.

Aphios Corporation has administrative offices, laboratories, and pilot plant facilities at 87 Main Street in North Reading, MA 01864, about 12 miles from central Boston. The facility includes office, conference, library, laboratory, and pilot plant manufacturing space.

Aphios's portfolio includes 70 issued U.S. and international patents, 34 pending patents, several trademarks, and know-how, covering therapeutic products and technologies for drug discovery, manufacturing, drug delivery, pathogen reduction, and virus inactivation.

Aphios has a library of marine microorganisms and marine molecule fractions from normal to extremophilic environments for the rapid discovery and development of therapeutics, with a focus on anti-infectives.

Sustainable, Earth-friendly nanotechnologies and pain therapeutics for chemotherapy induced nausea and vomiting, morning sickness and cancer treatment

Aphios provides service to the community by sponsoring internships, hosting site visits, providing mentorships and reviewing NIH grants.

Aphios develops biotechnology and nanotechnology drug delivery platforms and therapeutic products for health maintenance, disease prevention, and treatment of certain cancers, infectious diseases, and central nervous system disorders such as Alzheimer’s disease.

Aphios lists events it has attended and plans to attend this year.

Management and Directors of Aphios Corporation

Aphios Corporation 87 Main Street North Reading MA 01864 USA

Explore Aphios’ hybrid model of drug development and licensing powered by 87 patents and $50M in funding.